Congratulations to eGenesis, Inc., a cutting-edge bioengineering firm working in our Massachusetts-based lab portfolio, on securing $191M in Series D financing! This funding will support their first-in-human study for kidney transplants, as well as advance pipeline programs and scale production. #Biotech #KidneyTransplant #Healthpeak
We’re excited to announce our $191M Series D financing round led by Lux Capital with participation from existing investors ARCH Venture Partners, Khosla Ventures, Farallon Capital Management, Alta Partners, Fresenius Medical Care Ventures, and Leaps by Bayer as well as new investors DaVita Kidney Care, Eisai US Innovation, NATCO Pharma and Parkwood Corporation. Proceeds will be used to advance the company’s lead product candidate, EGEN-2784, to a first-in-human study for kidney transplant. The funding will also be used to advance pipeline programs as well as scale production. Read the release: 👇👇 https://lnkd.in/dU6QT-3E #organ #transplantation #biotech #funding